Letynol

Cefotaxime sodium, the active ingredient in Letynol, is a third‑generation cephalosporin presented as an injectable formulation for intramuscular use. It provides broad‑spectrum bactericidal activity against a range of Gram‑negative and Gram‑positive pathogens and is employed in the treatment of serious infections in hospitalized patients.

GNH USA supplies Letynol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards. The product is manufactured under strict GMP conditions and exported to multiple regions.

Cefotaxime sodium, a third‑generation cephalosporin, is used to treat serious bacterial infections across several organ systems.

- Severe bacterial infections: delivers rapid bactericidal action to eradicate the causative organisms. - Lower respiratory tract infections: improves clinical outcomes in pneumonia and bronchitis caused by susceptible pathogens. - Urinary tract infections: eliminates Gram‑negative uropathogens resistant to older agents. - Meningitis: achieves therapeutic concentrations in cerebrospinal fluid to treat central nervous system infections. - Skin and soft tissue infections: resolves cellulitis and wound infections caused by susceptible bacteria.

Cefotaxime sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: transient feeling of queasiness. - Vomiting: occasional emesis. - Injection site pain: local discomfort or erythema. - Rash: non‑specific skin eruption. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with respiratory distress. - Clostridioides difficile‑associated diarrhea: severe colitis. - Neutropenia: marked reduction in neutrophil count. - Thrombocytopenia: low platelet levels. - Renal impairment: acute kidney injury. - Stevens‑Johnson syndrome: severe mucocutaneous reaction.

When using Letynol, several precautionary measures should be observed to ensure safe administration. - Renal function: assess and adjust dose in patients with impaired renal clearance. - Allergy: avoid in individuals with known hypersensitivity to cephalosporins or penicillins. - Pregnancy: consider only if potential benefits outweigh potential risks. - Concomitant nephrotoxic drugs: monitor renal function closely. - Superinfection: watch for secondary infections such as fungal overgrowth. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cefotaxime sodium can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Probenecid: reduces renal excretion, increasing cefotaxime plasma levels. - Aminoglycosides: combined use may heighten risk of nephrotoxicity. - Warfarin: may potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in hormonal efficacy. - Diuretics: may affect renal clearance of cefotaxime. - Other β‑lactam antibiotics: additive toxicity, especially neurotoxicity.